Emerging drugs for psoriatic arthritis

Bibliography

• Gladman DD. Psoriatic arthritis. In: Harris ED Jr, Budd RC, Firestein GS, editors, Kelley's Textbook of Rheumatology. 7th edition. Saunders Elsevier, Philadelphia; 2005. p. 1155-64
   Google Scholar
• Scarpa R, Manguso F, D'Arienzo A, Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol 2000;27:1241-6
   PubMed Web of Science ®Google Scholar
• Queiro R, Torre JC, Belzunegui J, Clinical features and predictive factors in psoriatic arthritis-related uveitis. Semin Arthritis Rheum 2002;31:264-70
   PubMed Web of Science ®Google Scholar
• Mallbris L, Ritchlin CT, Stahle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep 2006;8:355-63
   PubMedGoogle Scholar
• Scarpa R, Ayala F, Caporaso N, Olivieri I. Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol 2006;33:210-2
   PubMed Web of Science ®Google Scholar
• Dougados M, van der Linden S, Juhlin R, The European Spondylarthropathy Study Group. Preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-27
   PubMed Web of Science ®Google Scholar
• Olivieri I, van Tubergen A, Salvarani C, van der Linden S. Seronegative spondyloarthritides. Best Pract Res Clin Rheumatol 2002;16:723-39
   PubMed Web of Science ®Google Scholar
• McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) 2003;42:778-83
   PubMed Web of Science ®Google Scholar
• Gladman DD, Stafford-Brady F, Chang CH, Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990;17:809-12
   PubMed Web of Science ®Google Scholar
• Torre-Alonso JC, Rodriguez-Perez A, Arribas Castrillo JM, Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 1991;30:245-50
   PubMedGoogle Scholar
• Wong K, Gladman DD, Husted J, Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997;40:1868-72
   PubMed Web of Science ®Google Scholar
• Punzi L, Pianon M, Rossini P, Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease. Ann Rheum Dis 1999;58:226-9
   PubMed Web of Science ®Google Scholar
• Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003;42:1460-8
   PubMed Web of Science ®Google Scholar
• Palazzi C, D'Agostino L, D'Amico E, Asymptomatic erosive peripheral psoriatic arthritis: a frequent finding in Italian patients. Rheumatology (Oxford) 2003;42:909-11
   PubMed Web of Science ®Google Scholar
• Scarpa R, Cuocolo A, Peluso R, Early psoriatic arthritis: the clinical spectrum. J Rheumatol 2008;35:137-41
   PubMed Web of Science ®Google Scholar
• Lindqvist UR, Alenius GM, Husmark T, The Swedish early psoriatic arthritis register – 2-year followup: a comparison with early rheumatoid arthritis. J Rheumatol 2008;35:668-73
   PubMed Web of Science ®Google Scholar
• Gladman DD, Farewell VT, Husted J, Wong K. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998;41:1103-10
   PubMed Web of Science ®Google Scholar
• Gladman DD. Disability and quality of life considerations. Psoriatic arthritis. In: Gordon GB, Ruderman E, editors. Psoriatic and psoriatic arthritis: an integral approach. Springer-Verlag, Heidelberg; 2005. p. 118-23
   Google Scholar
• Kavanaugh AF, Ritchlin CT, GRAPPA Treatment Guideline Committee. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 2006;33:1417-21
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Antoni CE, Gladman D, The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006;65:1038-43
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89
   PubMed Web of Science ®Google Scholar
• Olivieri I, D'Angelo S, Padula A, Palazzi C. The challenge of early diagnosis of psoriatic arthritis. J Rheumatol 2008;35:3-5
   PubMed Web of Science ®Google Scholar
• Gladman DD. Can we identify psoriatic arthritis early? Curr Rheumatol Rep 2008;10:419-21
   PubMedGoogle Scholar
• Olivieri I, D'Angelo S, Palazzi C, Padula A. Treatment strategies for early psoriatic arthritis. Expert Opin Pharmacother 2009;10:271-82
   PubMed Web of Science ®Google Scholar
• Anandarajah AP, Ritchlin CT. The diagnosis of early psoriatic arthritis. Nat Rev Rheumatol 2009;5:634-41
   PubMed Web of Science ®Google Scholar
• Husni ME, Meyer KH, Cohen DS, The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol 2007;57:581-7
   PubMed Web of Science ®Google Scholar
• Qureshi AA, Dominguez P, Duffin KC, Psoriatic screening tools. J Rheumatol 2008;35:1423-5
   PubMed Web of Science ®Google Scholar
• Gladman DD, Schentag CT, Tom BD, Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis 2009;68:497-501
   PubMed Web of Science ®Google Scholar
• Ibrahim GH, Buch MH, Lawson C, Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening tool (PEST) questionnaire. Clin Exp Rheumatol 2009;27:469-74
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Kavanaugh A, Gladman DD, Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94
   PubMed Web of Science ®Google Scholar
• Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006;33:1422-30
   PubMed Web of Science ®Google Scholar
• Nash P. Therapies for axial disease in psoriatic arthritis. J Rheumatol 2006;33:1431-4
   PubMed Web of Science ®Google Scholar
• Ritchlin CT. Therapies for psoriatic enthesopathy. A systematic review. J Rheumatol 2006;33:1435-8
   PubMed Web of Science ®Google Scholar
• Helliwell PS. Therapies for dactylitis in psoriatic arthritis. A systematic review. J Rheumatol 2006;33:1439-41
   PubMed Web of Science ®Google Scholar
• Strober BE, Siu K, Menon K. Conventional systemic agents for psoriasis. A systematic review. J Rheumatol 2006;33:1442-6
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Prinz J, Gottlieb AB. Biologic therapies for psoriasis. A systematic review. J Rheumatol 2006;33:1447-51
   PubMed Web of Science ®Google Scholar
• Cassell S, Kavanaugh AF. Therapies for psoriatic nail disease. A systematic review. J Rheumatol 2006;33:1452-6
   PubMed Web of Science ®Google Scholar
• Soriano ER, Rosa J. Update on the treatment of peripheral arthritis in psoriatic arthritis. Curr Rheumatol Rep 2009;11:270-7
   PubMedGoogle Scholar
• Kaltwasser JP, Nash P, Gladman D, Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50:1939-50
   PubMed Web of Science ®Google Scholar
• Antoni CE, Kavanaugh A, Kirkham B, Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227-36
   PubMed Web of Science ®Google Scholar
• Antoni C, Krueger GG, de Vlam K, Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90
   PubMed Web of Science ®Google Scholar
• Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and meta-analysis of randomized controlled trials. J Rheumatol 2008;35:883-90
   PubMed Web of Science ®Google Scholar
• Naldi L, Raho G. Emerging drugs for psoriasis. Expert Opin Emerg Drugs 2009;14:145-63
   PubMed Web of Science ®Google Scholar
• Spadaro A, Punzi L, Marchesoni A, Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. Rheumatology (Oxford) 2010, Doi:10.1093/rheumatology/keq008
   Google Scholar
• Palazzi C, Lubrano E, D'Angelo S, Olivieri I. Beyond early diagnosis: occult psoriatic arthritis. J Rheumatol 2010; In press
   Google Scholar
• Fitzgerald O, Winchester R. Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther 2009;11:214
   PubMed Web of Science ®Google Scholar
• Njobvu P, McGill P. Psoriatic arthritis and human immunodeficiency virus infection in Zambia. J Rheumatol 2000;27:1699-702
   PubMed Web of Science ®Google Scholar
• Rahman P, Elder JT. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005;64(Suppl 2):ii37-9
   PubMedGoogle Scholar
• Jongbloed SL, Lebre MC, Fraser AR, Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Res Ther 2006;8(1):R15
   PubMed Web of Science ®Google Scholar
• Curran SA, FitzGerald OM, Costello PJ, Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigens. J Immunol 2004;172:1935-44
   PubMed Web of Science ®Google Scholar
• Ritchlin CT. Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 2005;17:406-12
   PubMed Web of Science ®Google Scholar
• Villa-Forte A. Anticytokine therapy in non-rheumatoid arthritis indications in 2009. Curr Opin Rheumatol 2009;21:251-5
   PubMed Web of Science ®Google Scholar
• Slobodin G, Rosner I, Rozenbaum M, Psoriatic arthropathy: where now? Isr Med Assoc J 2009;11:430-4
   PubMed Web of Science ®Google Scholar
• Robinson H, Kelly S, Pitzalis C. Basic synovial biology and immunopathology in psoriatic arthritis. J Rheumatol 2009;83:14-6
   Google Scholar
• Alenius GM, Eriksson C, Rantapaa Dahlqvist S. Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis? Clin Exp Rheumatol 2009;27:120-3
   PubMed Web of Science ®Google Scholar
• MclInnes IB. Cytokine targeting in psoriasis and psoriatic arthritis: beyond TNFalpha. Ernst Schering Res Found Workshop 2006;56:29-44
   PubMedGoogle Scholar
• Palazzi C, D'Amico E, Cacciatore P, Juvenile onset of psoriasis arthritis in a patient with X-linked agammaglobulinemia (Bruton's disease). Scand J Rheumatol 2003;32:309-11
   PubMed Web of Science ®Google Scholar
• Baeten D, Kruithof E, Breban M, Tak PP. Spondylarthritis in the absence of B lymphocytes. Arthritis Rheum 2008;58:730-3
   PubMed Web of Science ®Google Scholar
• Kane D, Roth J, Frosch M, Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. Arthritis Rheum 2003;48:1676-85
   PubMed Web of Science ®Google Scholar
• Fearon U, Griosios K, Fraser A, Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 2003;30:260-8
   PubMed Web of Science ®Google Scholar
• Rihl M, Kruithof E, Barthel C, Involvement of neurotrophins and their receptors in spondyloarthritis synovitis: relation to inflammation and response to treatment. Ann Rheum Dis 2005;64:1542-9
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SK, Raychaudhuri SP. NGF and its receptor system: a new dimension in the pathogenesis of psoriasis and psoriatic arthritis. Ann NY Acad Sci 2009;1173:470-7
   PubMed Web of Science ®Google Scholar
• Colucci S, Brunetti G, Cantatore FP, Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. J Pathol 2007;212:47-55
   PubMed Web of Science ®Google Scholar
• Mori G, Cantatore FP, Brunetti G, Synovial fluid fibroblasts and lymphocytes support the osteoclastogenesis in human psoriatic arthritis. Ann NY Acad Sci 2007;1117:159-64
   PubMed Web of Science ®Google Scholar
• Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005;115:1571-9
   PubMed Web of Science ®Google Scholar
• Grcevic D, Jajic Z, Kovacic N, Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factor-superfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness. J Rheumatol 2010;37:246-56
   PubMed Web of Science ®Google Scholar
• McGonagle D. Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatol Venereol 2009;23(Suppl 1):9-13
   PubMed Web of Science ®Google Scholar
• Available from: http://www.who.int/ ictrp/en/
   Google Scholar
• Kang JS, DeLuca PP, Lee KC. Emerging PEGylated drugs. Expert Opin Emerg Drugs 2009:14:363-80
   PubMed Web of Science ®Google Scholar
• Oussalah A, Bigard MA, Peyrin-Biroulet L. Certolizumab use in pregnancy. Gut 2009;58:608
   PubMed Web of Science ®Google Scholar
• Smolen J, Landewé RB, Mease P, Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797-804
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Vencovsky J, van Vollenhoven RF, Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009;68:805-11
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Reich K, Sterry W, Terpstra I. Safety and efficacy (PASI 90 and global evaluation) of subcutaneous certolizumab pegol in patients with moderate to severe chronic plaque psoriasis: Results from a double-blind, placebo-controlled trial. J Am Acad Dermatol 2008;58(Suppl 2):AB4
   Web of Science ®Google Scholar
• Kavanaugh A, McInnes I, Mease P, Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86
   PubMed Web of Science ®Google Scholar
• Mease PJ, Hobbs K, Chalmers A, Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study. Ann Rheum Dis 2009;68:1247-54
   PubMed Web of Science ®Google Scholar
• Bensen W, Cardiel MH, Forejtova S, Results of a phase 2 randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R type I) in patients with rheumatoid arthritis. Arthritis Rheum 2008;58(Suppl 9):S535
   Google Scholar
• Church LD, McDermott MF. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther 2009;11:81-9
   PubMed Web of Science ®Google Scholar
• Murphy CA, Langrish CL, Chen Y, Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003;198:1951-7
   PubMed Web of Science ®Google Scholar
• Malfait AM, Butler DM, Presky DH, Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin Exp Immunol 1998;111:377-83
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Menter A, Mendelsohn A, Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009;373:633-40
   PubMed Web of Science ®Google Scholar
• Kimball AB, Gordon KB, Langley RG, ABT-874 Psoriasis Study Investigators. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008;144:200-7
   PubMed Web of Science ®Google Scholar
• Tak PP, Durez P, Gomez-Reino JJ, AIN457 shows a good safety profile and clinical benefit in patients with active rheumatoid arthritis (RA) despite methotrexate therapy: 16-weeks results from a randomized proof-of-concept trial. Arthritis Rheum 2009;60(Suppl 10):1922
   Google Scholar
• Genovese MC, van den Bosch F, Roberson SA, LY2439821, a novel anti-IL-17 Mab: safety, tolerability and efficacy in patients with RA on background DMARDs. Arthritis Rheum 2009;60(Suppl 10):415
   Google Scholar
• Westhovens R, Verschueren P. Translating co-stimulation blockade into clinical practice. Arthritis Res Ther 2008;10(Suppl 1):S4
   PubMed Web of Science ®Google Scholar
• Canete JD, Celis R, Hernandez V, Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis. Ann Rheum Dis 2009, Doi:10.1136/ard.2009.113233
   Web of Science ®Google Scholar
• Olivieri I, D'Angelo S, Mennillo GA, Abatacept in spondyloarthritis refractory to tumour necrosis factor alpha inhibition. Ann Rheum Dis 2009;68:151-2
   PubMed Web of Science ®Google Scholar
• Vieira FJ, Callado MR, Vieira WP. Abatacept as an option therapy in difficult to treat psoriatic arthritis. Rheumatology Int 2010;30:849-50
   PubMed Web of Science ®Google Scholar
• Canete JD, Santiago B, Cantaert T, Ectopic lymphoid neogenesis in psoriatic arthritis. Ann Rheum Dis 2007;66:720-6
   PubMed Web of Science ®Google Scholar
• Cohen JD. Successful treatment of psoriatic arthritis with rituximab. Ann Rheum Dis 2008;67:1647-8
   PubMed Web of Science ®Google Scholar
• Mielke F, Schneider-Obermeyer J, Dorner T. Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma. Ann Rheum Dis 2008;67:1056-7
   PubMed Web of Science ®Google Scholar
• Nocturne G, Dougados M, Constantin A, Rituximab in the spondyloarthropathies: data of eight patients followed up in the French Autoimmunity and Rituximab (AIR) registry. Ann Rheum Dis 2010;69:471-2
   PubMed Web of Science ®Google Scholar
• Dorner T, Burmester GR. New approaches of B-cell-directed therapy: beyond rituximab. Curr Opin Rheumatol 2008;20:263-8
   PubMed Web of Science ®Google Scholar
• Tak PP, Thurlings RM, Rossier C, Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated dose study. Arthritis Rheum 2008;58:61-72
   PubMed Web of Science ®Google Scholar
• West K. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Investig Drugs 2009;10:491-504
   PubMed Web of Science ®Google Scholar
• Boy MG, Wang C, Wilkinson BE, Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol 2009;129:2299-302
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kavanaugh A, Burgos Vargas R, Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve week, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:3309-18
   PubMed Web of Science ®Google Scholar
• Tebib J, Mariette X, Bourgeois P, Masitinib in the treatment of active rheumatoid arthritis: results of multicentre, open-label, dose ranging, phase 2a study. Arthritis Res Ther 2009;11:R95
   PubMed Web of Science ®Google Scholar
• Schett G, Zwerina J, Firestein G. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 2008;67:909-16
   PubMed Web of Science ®Google Scholar
• Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009;60:1232-41
   PubMed Web of Science ®Google Scholar
• Mease PJ, Reich K. Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2009;60:402-11
   PubMed Web of Science ®Google Scholar
• Cummings SR, San Martin J, McClung MR, Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Eng J Med 2009;361:756-65
   PubMed Web of Science ®Google Scholar
• Dore RK, Cohen SB, Lane NE, Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2009, Doi:10.1136/ard.2009.112920
   Web of Science ®Google Scholar
• Gottlieb AB, Strober B, Krueger JG, An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 2008;24:1529-38
   PubMed Web of Science ®Google Scholar
• McInnes I, Martin R, Zimmermann-Gorska I, Safety and efficacy of a human monoclonal antibody to IL-15 (AMG 714) in patients with rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Ann Rheum Dis 2006;65(Suppl II):60
   Google Scholar